Intended for healthcare professionals


FDA committee votes for warning labels on stimulant drugs

BMJ 2006; 332 doi: (Published 16 February 2006) Cite this as: BMJ 2006;332:380
  1. Fred Charatan
  1. Florida

    An advisory committee of the Food and Drug Administration voted by 8-7 last week to require drug companies to display a “black box” warning label on several stimulant drugs used to treat attention-deficit/hyperactivity disorder.

    The drugs are methylphenidate hydrochloride (sold as Ritalin and Concerta) and the amphetamine formulation sold in the United States as Adderall.

    The committee, whose recommendation was unexpected, said the warning was …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription